<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154551">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01700491</url>
  </required_header>
  <id_info>
    <org_study_id>B2012:038</org_study_id>
    <nct_id>NCT01700491</nct_id>
  </id_info>
  <brief_title>Pilot Study: Paravertebral Analgesia vs Epidural Analgesia After Thoracotomy</brief_title>
  <acronym>ParaEpi</acronym>
  <official_title>Pilot Study: A Non-Inferiority Trial of the Analgesic Effect of Paravertebral Analgesia to Epidural Analgesia for the Management of Post-Operative Pain After Thoracotomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Anesthesia and Perioperative Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Surgery</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Paravertebral analgesia is non-inferior to epidural analgesia for pain control and superior
      to epidural analgesia in terms of the main complication of hypotension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is some evidence that paravertebral analgesia is similar to epidural analgesia in
      efficacy but superior in maintenance of blood pressure. This is a double blind, randomized
      control trial comparing paravertebral catheters to epidural catheters for the management of
      post thoracotomy analgesia.  Both groups will undergo placement of a pre-induction epidural
      catheter as well as a surgically placed paravertebral catheter.  Patients will also receive
      PCA morphine.  The primary outcome will be daily morphine use measured in milligrams.  The
      co-primary outcome will be time spent with a systolic blood pressure below 90mmHg.  Outcomes
      will be measured during the first five postoperative days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">April 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Analgesic Effect</measure>
    <time_frame>At postoperative day 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total cumulative dose of morphine equivalent narcotics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypotension</measure>
    <time_frame>At postoperative day 5</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Cumulative time in which the systolic blood pressure is below 90mmHg.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hypotension</condition>
  <arm_group>
    <arm_group_label>Epidural Catheter 0.2% ropivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive an infusion of 0.2% ropivacaine at a range of 0-10 mL/hr through an epidural catheter.  They will also receive an infusion of saline  at a rate of 0-10 mL/hr through a paravertebral catheter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paravertebral Catheter 0.4% ropivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive an infusion of 0.4% ropivacaine at a range of 0-10mL/hr through a paravertebral catheter.  They will also receive an infusion of saline at a range of 0-10mL/hr through an epidural catheter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epidural Catheter 0.2% ropivacaine</intervention_name>
    <description>0.2% ropivacaine into epidural space and saline into paravertebral space</description>
    <arm_group_label>Epidural Catheter 0.2% ropivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paravertebral Catheter 0.4% ropivacaine</intervention_name>
    <description>0.4% ropivacaine into paravertebral space and saline into the epidural space</description>
    <arm_group_label>Paravertebral Catheter 0.4% ropivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Open thoracotomy

          -  Age &gt; 18 yo

          -  Able to use a patient controlled analgesia device

        Exclusion Criteria:

          -  Previous thoracotomy

          -  Previous spine surgery

          -  Chronic pain condition

          -  Ongoing narcotic use

          -  Prior narcotic abuse

          -  Active chest infection

          -  Chest trauma

          -  Anticoagulation

          -  Other contraindication to epidural catheter placement

          -  Allergy to local anesthetic or narcotic
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sadeesh Srinathan, MD, FRCS C-Th, FRCS(C)</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Kowalski, MD, FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rob Brown, MD, FRCP</last_name>
    <role>Study Director</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Purnima Rao, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sadeesh Srinathan, Medicine</last_name>
    <phone>(204) 787-7143</phone>
    <email>ssrinathan@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Purnima Rao, Medicine</last_name>
    <phone>(204) 688-6309</phone>
    <email>umrao@cc.umanitoba.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ryan Pauls, MD FRCS(C)</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rob Brown, MD FRCP(C)</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Purnima Rao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sadeesh Srinathan, MD, FRCS</last_name>
      <phone>2047873791</phone>
    </contact>
    <investigator>
      <last_name>Sadeesh Srinathan, MD, FRCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 12, 2013</lastchanged_date>
  <firstreceived_date>September 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Manitoba</investigator_affiliation>
    <investigator_full_name>Sadeesh Srinathan, MD</investigator_full_name>
    <investigator_title>Assistant Professor- Department of Thoracic Surgery</investigator_title>
  </responsible_party>
  <keyword>Paravertebral Catheter</keyword>
  <keyword>Epidural Catheter</keyword>
  <keyword>Analgesia</keyword>
  <keyword>Hypotension</keyword>
  <keyword>Analgesia,Epidural</keyword>
  <keyword>Analgesia,Paravertebral</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
